Altogether, these studies suggest that local activation of hepatic PPARγ may promote ectopic fat deposition in the liver whereas systemic activation of PPARγ may promote fat deposition in adipose tissue rather than liver leading to clinical improvements of metabolic syndromes including hepatic steatosis. The gene discussed is PPARG; the disease is metabolic syndrome.